title: Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen.
abstract: In order to evaluate the efficacy of two different sequences of second and third line hormonotherapy in advanced post-menopausal breast cancer, 257 women aged 36-91 years (mean age: 63.6 years) who had become resistant to tamoxifen (TAM), entered into a multicenter randomized trial comparing two different regimens: 1) Aminoglutethimide (Ag) 500 mg/day with hydrocortisone supplementation from 30 to 60 mg/day; and 2) oral medroxyprogesterone acetate (MPA) 500 mg twice a day. 250 patients were evaluated following second line hormone therapy and, after cross-over, 128 following third line hormonotherapy. No significant difference was observed, during either second or third line therapies, for toxicity, survival, or response rate; however, in both second and third line therapies the median time to progression was significantly longer with Ag therapy.
authors.affiliation: Institut Curie, Paris, France.
authors.forename: E
authors.initials: E
authors.lastname: Garcia-Giralt
authors.forename: Y
authors.initials: Y
authors.lastname: Ayme
authors.forename: M
authors.initials: M
authors.lastname: Carton
authors.forename: A
authors.initials: A
authors.lastname: Daban
authors.forename: T
authors.initials: T
authors.lastname: Delozier
authors.forename: P
authors.initials: P
authors.lastname: Fargeot
authors.forename: P
authors.initials: P
authors.lastname: Fumoleau
authors.forename: A
authors.initials: A
authors.lastname: Gorins
authors.forename: D
authors.initials: D
authors.lastname: Guerin
authors.forename: R
authors.initials: R
authors.lastname: Guerin
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000616:Aminoglutethimide / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use*; D008593:Menopause; D008875:Middle Aged; D011446:Prospective Studies; D013629:Tamoxifen / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D013629:Tamoxifen; D000616:Aminoglutethimide; D017258:Medroxyprogesterone Acetate